The UK trial landscape is broader than you might think
Britain has become one of the busiest places in Europe for diabetes research, and not just inside university labs. A lot of it now happens in routine NHS care, which makes the findings more realistic and the routes in more varied. The NHS Type 2 Diabetes Path to Remission Programme, sometimes called the soups and shakes scheme, uses a 12-week total diet replacement followed by a gradual return to food. Recent evaluations of the real-world rollout found that around a third of people who completed it reached remission within a year, with meaningful reductions in HbA1c and weight. That is not a controlled lab result. It is evidence from ordinary GP referrals across England.
For type 1 diabetes, the picture has shifted just as sharply. Hybrid closed-loop systems, which pair an insulin pump with a continuous glucose monitor, have moved from specialist pilots towards broader NHS availability. One English pilot covering 420 adults across 30 diabetes centres reported a notable drop in HbA1c, with time in range climbing from roughly a third to nearer two thirds of the day. Separate studies in children and young people with high HbA1c are showing similar patterns in real-world settings. Meanwhile, the FreeDM2 results published this year found that people with type 2 diabetes on basal insulin who used a Libre-style sensor spent about two and a half extra hours per day in a healthy glucose range compared with finger-prick testing. Small changes in daily routine, but large shifts in day-to-day wellbeing.
Comparing the main types of diabetes trial in the UK
| Type of study | Example you may encounter | Typical participants | What it involves | Main benefit | Things to weigh up |
|---|
| NHS lifestyle and remission programme | Type 2 Diabetes Path to Remission | Adults 18–65, diagnosed within last 6 years, BMI above threshold | 12-month behavioural programme with an initial meal-replacement phase | Weight loss and possible remission | The early diet phase needs real commitment |
| Continuous glucose monitoring study | FreeStyle Libre-style CGM for type 2 on insulin | Adults with type 2 using basal insulin | Wearing a sensor, fewer finger-pricks, regular data review | More time in range, less guesswork | Sensor changes and data appointments |
| Hybrid closed-loop (type 1) | Automated insulin delivery pilots | Children, young people and adults with elevated HbA1c | Device training, frequent clinic touchpoints | Lower HbA1c, lighter daily burden | Learning curve with the technology |
| Early-phase drug study | AZP-531-style investigational treatment | Adults 18–65 on metformin, certain BMI band | Inpatient stays and multiple clinic visits | Contribution to future treatments, paid compensation | Time away from home, unknown effects |
| Lifestyle and digital wellbeing study | Omega-3, beetroot juice or emotional support apps | Adults with prediabetes or type 2 diabetes | Home or clinic visits over weeks or months | Low risk, flexible, often remote | Effects may be modest |
Why many people hesitate to take part
Despite the range of opportunities, participation still lags behind demand. Three hurdles keep coming up in conversations with patients. The first is simply finding a trustworthy trial, because listings are scattered across the ClinicalTrials.gov registry, the ISRCTN database and charity pages, and each uses different language. The second is eligibility. Many studies set tight windows on age, BMI, time since diagnosis and current medication, so someone who is keen can still be turned away for reasons that have nothing to do with their health. The third is practical: a large share of sites sit in cities such as Birmingham, Blackpool, Bristol, Newcastle and Coleraine, which raises questions about travel, time off work and whether expenses are covered.
There is also a quieter worry about placebos. It is worth understanding that not every study uses a dummy treatment. Real-world NHS evaluations, lifestyle programmes and device studies usually involve no placebo at all, because everyone receives the active intervention. Only certain early-phase drug trials compare against a placebo, and those are clearly explained before you consent.
Finding the right diabetes trial: a practical route in
Start with the people who already know your care
Your GP or diabetes specialist nurse is the quickest filter. They can tell you whether you fit common entry criteria, whether a study would clash with your current medication, and whether a local trust is recruiting. Many NHS hospital trusts run their own research lists, so simply asking at your next review can open doors that never appear in a general web search.
Use the national registers and listings
Charity and public registers exist specifically to match people to suitable studies. The Diabetes UK clinical trials page lists current opportunities across the country and is updated regularly. People in north-west England can register with Research for the Future, run by Manchester University NHS Foundation Trust, to hear about local NHS diabetes research. Those in Scotland can join the NHS Research Scotland Diabetes Register to be matched with type 1 related opportunities. Breakthrough T1D UK maintains its own list for type 1 studies, including the T1D-Plus project for adults diagnosed within the last six weeks. For a wider sweep, ISRCTN and ClinicalTrials.gov both let you filter by condition and location, though the language there is more technical.
Take the example of Anna, a 52-year-old teacher from Bristol who had lived with type 2 diabetes for nine years. Her practice nurse mentioned a sensor-based study during a routine appointment. Anna qualified, attended three short visits, and came away with a clearer picture of how her glucose behaved after school-day meals than she had managed in years. No experimental drug, no inpatient stay, just better information she could act on.
Ask the questions that matter before you sign
A good study team will welcome questions. Ask what phase the research is in, how it will change your usual care, and whether your routine diabetes medication continues throughout. Clarify who covers travel and parking, and whether there is any compensation for your time. Some commercial early-phase trials advertise payments in the region of £3,000 to £4,000 for inpatient studies, while most NHS research covers expenses rather than offering payment. Also ask what happens once the study ends, whether you receive your own results, and how any new findings will be shared. You are entitled to leave at any point without giving a reason, and withdrawing never affects your ongoing NHS care.
Keeping expectations realistic
Participation does not promise a cure, and it should never be framed as such. What it offers is closer monitoring, access to emerging treatments and technology, and a chance to shape how diabetes care is delivered in the UK. The strongest outcomes in recent years, from remission rates in the Path to Remission programme to time in range gains in CGM studies, all came from people who showed up consistently over several months. The real value builds through that process, not through a single appointment.
If you are curious about diabetes management trials, the most sensible first step is a conversation with your diabetes team, followed by a browse of the Diabetes UK clinical trials page. Registering your interest costs nothing beyond a few minutes, and it carries no obligation to take part. The trials need people who reflect the real mix of ages, backgrounds and treatment histories, because research that only includes one type of patient helps fewer people in the end. Your experience, however ordinary it feels to you, is exactly the data that makes future care better.
研究の知恵